A practical reference on RP-HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-18 and is reviewed periodically as new material appears.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
| Property | Value | Notes |
|---|---|---|
| Primary reported target | Hepatocyte growth factor/c-Met signaling | Findings mainly from cell and animal studies. |
| Related endogenous peptide | Angiotensin IV | Dihexa is described as a stabilized analog. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for purity assessment. |
| Identity confirmation | Mass spectrometry | Provides a molecular mass check. |
| Regulatory status | Not approved for human use | Sold as a research chemical in many jurisdictions. |
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
=== Distance restraints === A crosspeak in a NOESY experiment signifies spatial proximity between the two nuclei in question. Thus each peak can be converted into a maximum distance between the nuclei, usually between 1.8 and 6 angstroms. The intensity of a NOESY peak is proportional to the distance to the minus 6th power, so the distance is determined according to the intensity of the peak. The intensity-distance relationship is not exact, so usually a distance range is used. It is important to assign the NOESY peaks to the correct nuclei based on the chemical shifts. If this task is performed manually, it is usually very labor-intensive since proteins usually have thousands of NOESY peaks. Some computer programs such as PASD/XPLOR-NIH, UNIO, CYANA, ARIA/CNS, and AUDANA/PONDEROSA-C/S in the Integrative NMR platform perform this task automatically on manually pre-processed listings of peak positions and peak volumes, coupled to a structure calculation. Direct access to the raw NOESY data without the cumbersome need of iteratively refined peak lists is so far only granted by the PASD algorithm implemented in XPLOR-NIH, the ATNOS/CANDID approach implemented in the UNIO software package, and the PONDEROSA-C/S and thus indeed guarantees objective and efficient NOESY spectral analysis. To obtain as accurate assignments as possible, it is a great advantage to have access to carbon-13 and nitrogen-15 NOESY experiments, since they help to resolve overlap in the proton dimension. This leads to faster and more reliable assignments, and in turn to better structures.
=== 2025: Australian Open final, 500th win === Alongside Team Germany, Zverev failed to defend the United Cup after withdrawing from the event due to injury. Entering the 2025 Australian Open as the second seed for the first time in his career, Zverev began his tournament with a dominant victory over 2019 semifinalist Lucas Pouille in the first round. He reached his second consecutive and third overall semifinal at the Australian Open defeating Pedro Martínez, Jacob Fearnley, Ugo Humbert, and Tommy Paul. Against the 24-time major champion, Zverev won the 81-minute first set against Djokovic before the latter's retirement due to injury, advancing to his third major final. In the final, Zverev lost to defending champion Jannik Sinner in straight sets. Following his defeat to Sinner, a visibly distraught Zverev delivered an emotional speech during the trophy ceremony, stating, "I want to thank my team... I'm just not good enough. It's as simple as that." In the post-match press conference, he reflected on his career trajectory and the pressure of being a perennial contender without a Major title, reportedly remarking that he "didn't want to be the best player in history without a Grand Slam", expressing his desperation to finally break the barrier after losing his third major final. Over the next two months, Zverev made quarterfinals at the South American events he played in, Buenos Aires and Rio de Janeiro, losing to Argentines Francisco Cerundolo and Francisco Comesana, respectively.
The influx of refugees troubled the Cossacks, not only because of the increased demand for food but also because their large number meant the Cossacks could not absorb them into their culture by way of the traditional apprenticeship. Instead of taking these steps for proper assimilation into Cossack society, the runaway peasants spontaneously declared themselves Cossacks and lived alongside the true Cossacks, laboring or working as barge-haulers to earn food. Divisions among the Cossacks began to emerge as conditions worsened and Mikhail's son Alexis took the throne. Older Cossacks began to settle and become prosperous, enjoying privileges earned through obeying and assisting the Muscovite system. The old Cossacks started giving up the traditions and liberties that had been worth dying for, to obtain the pleasures of an elite life. The lawless and restless runaway peasants who called themselves Cossacks looked for adventure and revenge against the nobility that had caused them suffering. These Cossacks did not receive the government subsidies that the old Cossacks enjoyed, and had to work harder and longer for food and money.
Sources: en.wikipedia.org
Ricky Dyson (born 28 September 1985) is a former professional Australian rules footballer who played for the Essendon Football Club in the Australian Football League (AFL). Originally from the Epping Football Club, and drafted at number 44 in the 2003 National Draft, Dyson played mainly as a midfielder.
== Research == As of March 2019, oral levoketoconazole (developmental code name COR-003, tentative brand name Recorlev) is phase III clinical trials for the treatment of Cushing's syndrome. Oral levoketoconazole may have a lower risk of liver toxicity than oral ketoconazole.
AMP + diphosphate + NAD+ The 3 substrates of this enzyme are ATP, deamido-NAD+, and NH3, whereas its 3 products are AMP, diphosphate, and NAD+. This enzyme belongs to the family of ligases, specifically those forming carbon-nitrogen bonds as acid-D-ammonia (or amine) ligases (amide synthetase). The systematic name of this enzyme class is deamido-NAD+:ammonia ligase (AMP-forming). Other names in common use include NAD+ synthetase, NAD+ synthetase, nicotinamide adenine dinucleotide synthetase, and diphosphopyridine nucleotide synthetase. This enzyme participates in nicotinate and nicotinamide metabolism and nitrogen metabolism.
Sources: en.wikipedia.org
WJ0679 is a small-molecule oxytocin receptor agonist and vasopressin receptor antagonist. It acts specifically as a very weak partial agonist of the oxytocin receptor (Ki = 422 nM; EC50Tooltip half-maximal effective concentration = 406 nM; EmaxTooltip maximal efficacy = 13%) and as an antagonist of the vasopressin V1A receptor (Ki = 105 nM; IC50Tooltip half-maximal inhibitory concentration = 2,203 nM), whereas no data were reported for the vasopressin V2 receptor. Despite its low activational efficacy at the oxytocin receptor, WJ0679 induces prosocial effects, including increased time spent in close physical contact and increased active social investigation, in rodents. The chemical synthesis of WJ0679 has been described. Along with its close analogue CA7, WJ0679 has the smallest chemical structure known for an oxytocin receptor agonist, with WJ0679 having about 60% of the molecular weight of LIT-001 and both WJ0679 and CA7 lacking LIT-001's tail component. Many analogues of WJ0679 and CA7 have been described. WJ0679 was first described in the scientific literature by a group including Michael Kassiou, Michael Bowen, Iain McGregor, and others at the University of Sydney in 2018. This group has founded a startup pharmaceutical company called Kinoxis Therapeutics and is developing small-molecule oxytocin-related drugs like KNX-100 and the KNX-200 series for potential medical use as of the 2020s.
Absolute bioavailability compares the bioavailability of the active drug in systemic circulation following non-intravenous administration (i.e., after oral, buccal, ocular, nasal, rectal, transdermal, subcutaneous, or sublingual administration), with the bioavailability of the same drug following intravenous administration. It is the fraction of exposure to a drug (AUC) through non-intravenous administration compared with the corresponding intravenous administration of the same drug. The comparison must be dose normalized (e.g., account for different doses or varying weights of the subjects); consequently, the amount absorbed is corrected by dividing the corresponding dose administered. In pharmacology, in order to determine absolute bioavailability of a drug, a pharmacokinetic study must be done to obtain a plasma drug concentration vs time plot for the drug after both intravenous (iv) and extravascular (non-intravenous, i.e., oral) administration. The absolute bioavailability is the dose-corrected area under curve (AUC) non-intravenous divided by AUC intravenous. The formula for calculating the absolute bioavailability, F, of a drug administered orally (po) is given below (where D is dose administered).
A wide variety of neptunium sulfide compounds have been characterized, including the pure sulfide compounds NpS, NpS3, Np2S5, Np3S5, Np2S3, and Np3S4. Of these, Np2S3, prepared by reacting NpO2 with hydrogen sulfide and carbon disulfide at around 1000 °C, is the most well-studied and three allotropic forms are known. The α form exists up to around 1230 °C, the β up to 1530 °C, and the γ form, which can also exist as Np3S4, at higher temperatures. NpS can be produced by reacting Np2S3 and neptunium metal at 1600 °C and Np3S5 can be prepared by the decomposition of Np2S3 at 500 °C or by reacting sulfur and neptunium hydride at 650 °C. Np2S5 is made by heating a mixture of Np3S5 and pure sulfur to 500 °C. All of the neptunium sulfides except for the β and γ forms of Np2S3 are isostructural with the equivalent uranium sulfide and several, including NpS, α−Np2S3, and β−Np2S3 are also isostructural with the equivalent plutonium sulfide. The oxysulfides NpOS, Np4O4S3, and Np2O2S have also been produced, although the latter two have not been well studied. NpOS was first prepared in 1985 by vacuum sealing NpO2, Np3S5, and pure sulfur in a quartz tube and heating it to 900 °C for one week. Neptunium selenide compounds that have been reported include NpSe, NpSe3, Np2Se3, Np2Se5, Np3Se4, and Np3Se5. All of these have only been obtained by heating neptunium hydride and selenium metal to various temperatures in a vacuum for an extended period of time and Np2Se3 is only known to exist in the γ allotrope at relatively high temperatures.
Sources: en.wikipedia.org
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.
Reverse-phase high-performance liquid chromatography is commonly used to assess purity. Mass spectrometry is used to confirm molecular identity. These methods are typical for synthetic peptides and research chemicals.
Dihexa is not approved as a drug in major jurisdictions. It is often sold as a research chemical, which is not the same as a medicine. Its legal status can vary by country and may change.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.